Antimicrobial Peptides Derived from Bacteria: Classification, Sources, and Mechanism of Action against Multidrug-Resistant Bacteria.

Raynichka Mihaylova-Garnizova, Slavena Davidova, Yordan Hodzhev, Galina Satchanska
Author Information
  1. Raynichka Mihaylova-Garnizova: Department of Natural Sciences, New Bulgarian University, Montevideo Blvd. 21, 1618 Sofia, Bulgaria.
  2. Slavena Davidova: Department of Natural Sciences, New Bulgarian University, Montevideo Blvd. 21, 1618 Sofia, Bulgaria.
  3. Yordan Hodzhev: Department of Natural Sciences, New Bulgarian University, Montevideo Blvd. 21, 1618 Sofia, Bulgaria. ORCID
  4. Galina Satchanska: Department of Natural Sciences, New Bulgarian University, Montevideo Blvd. 21, 1618 Sofia, Bulgaria.

Abstract

Antimicrobial peptides (AMPs) are short, usually cationic peptides with an amphiphilic structure, which allows them to easily bind and interact with the cellular membranes of viruses, bacteria, fungi, and other pathogens. bacterial AMPs, or bacteriocins, can be produced from Gram-negative and Gram-positive bacteria via ribosomal synthesis to eliminate competing organisms. bacterial AMPs are vital in addressing the increasing antibiotic resistance of various pathogens, potentially serving as an alternative to ineffective antibiotics. Bacteriocins have a narrow spectrum of action, making them highly specific antibacterial compounds that target particular bacterial pathogens. This review covers the two main groups of bacteriocins produced by Gram-negative and Gram-positive bacteria, their modes of action, classification, sources of positive effects they can play on the human body, and their limitations and future perspectives as an alternative to antibiotics.

Keywords

References

  1. Int J Mol Sci. 2024 Apr 29;25(9): [PMID: 38732089]
  2. J Clin Lab Anal. 2022 Jan;36(1):e24093 [PMID: 34851542]
  3. J Adv Res. 2019 Apr 23;19:75-84 [PMID: 31341672]
  4. Int J Mol Sci. 2022 Jan 04;23(1): [PMID: 35008951]
  5. Antibiotics (Basel). 2023 Sep 02;12(9): [PMID: 37760697]
  6. Drug Resist Updat. 2023 May;68:100954 [PMID: 36905712]
  7. Antibiotics (Basel). 2022 Oct 16;11(10): [PMID: 36290075]
  8. Int J Mol Sci. 2023 Apr 05;24(7): [PMID: 37047760]
  9. Biochemistry (Mosc). 2019 May;84(5):464-478 [PMID: 31234762]
  10. Int J Med Microbiol. 2014 Jan;304(1):63-71 [PMID: 24119540]
  11. Protein Pept Lett. 2020;27(2):120-134 [PMID: 31553285]
  12. Int J Mol Sci. 2023 Dec 16;24(24): [PMID: 38139385]
  13. Life (Basel). 2023 Jul 07;13(7): [PMID: 37511896]
  14. Sci Rep. 2024 Jan 22;14(1):1894 [PMID: 38253659]
  15. Mar Drugs. 2019 Aug 28;17(9): [PMID: 31466341]
  16. Antibiotics (Basel). 2021 Dec 24;11(1): [PMID: 35052897]
  17. Molecules. 2021 Sep 13;26(18): [PMID: 34577022]
  18. Int J Antimicrob Agents. 2019 Dec;54(6):771-779 [PMID: 31374334]
  19. Pharmaceutics. 2022 Mar 15;14(3): [PMID: 35336016]
  20. Nat Microbiol. 2016 Sep 12;1(11):16162 [PMID: 27617798]
  21. Viruses. 2021 May 14;13(5): [PMID: 34069206]
  22. Curr Opin Pharmacol. 2006 Oct;6(5):468-72 [PMID: 16890021]
  23. Pharmaceuticals (Basel). 2021 Sep 23;14(10): [PMID: 34681180]
  24. World J Microbiol Biotechnol. 2018 Mar 29;34(4):57 [PMID: 29594558]
  25. Drug Discov Ther. 2022 May 17;16(2):55-62 [PMID: 35466124]
  26. J Microbiol. 2023 Jun;61(6):641-648 [PMID: 37306831]
  27. Chem Soc Rev. 2021 Jul 5;50(13):7820-7880 [PMID: 34042120]
  28. Antibiotics (Basel). 2024 Feb 20;13(3): [PMID: 38534631]
  29. Signal Transduct Target Ther. 2022 Feb 14;7(1):48 [PMID: 35165272]
  30. Microbiol Mol Biol Rev. 2007 Mar;71(1):158-229 [PMID: 17347522]
  31. Probiotics Antimicrob Proteins. 2019 Jun;11(2):370-381 [PMID: 30229514]
  32. Cell Mol Biol (Noisy-le-grand). 2017 Oct 31;63(10):20-32 [PMID: 29096754]
  33. Antibiotics (Basel). 2024 Feb 21;13(3): [PMID: 38534637]
  34. Appl Microbiol Biotechnol. 2023 Sep;107(18):5569-5593 [PMID: 37450018]
  35. J Mol Microbiol Biotechnol. 2007;13(4):194-9 [PMID: 17827969]
  36. Sci Rep. 2020 Jan 22;10(1):944 [PMID: 31969663]
  37. Int J Mol Sci. 2021 Oct 22;22(21): [PMID: 34768832]
  38. Front Chem. 2021 Jun 18;9:691532 [PMID: 34222199]
  39. Nat Biotechnol. 2022 Jun;40(6):921-931 [PMID: 35241840]
  40. Nat Microbiol. 2023 Dec;8(12):2420-2434 [PMID: 37973865]
  41. Colloids Surf B Biointerfaces. 2022 Sep;217:112693 [PMID: 35853393]
  42. ACS Cent Sci. 2022 Aug 24;8(8):1209-1217 [PMID: 36032765]
  43. Mil Med Res. 2021 Sep 9;8(1):48 [PMID: 34496967]
  44. Can J Microbiol. 2021 Feb;67(2):119-137 [PMID: 32783775]
  45. Drug Des Devel Ther. 2017 Nov 03;11:3159-3170 [PMID: 29138537]
  46. Nat Biotechnol. 2019 Oct;37(10):1186-1197 [PMID: 31427820]
  47. Microorganisms. 2021 Oct 07;9(10): [PMID: 34683428]
  48. Res Microbiol. 2019 Nov - Dec;170(8):399-406 [PMID: 31401108]
  49. FEMS Microbiol Rev. 2022 Jan 18;46(1): [PMID: 34410368]
  50. Appl Microbiol Biotechnol. 2016 Apr;100(7):2939-51 [PMID: 26860942]
  51. Clin Microbiol Rev. 2017 Apr;30(2):557-596 [PMID: 28275006]
  52. Antibiotics (Basel). 2020 Jan 21;9(2): [PMID: 31973108]
  53. Microb Drug Resist. 2018 Jul/Aug;24(6):747-767 [PMID: 29957118]
  54. J Appl Microbiol. 2012 Oct;113(4):723-36 [PMID: 22583565]
  55. Antibiotics (Basel). 2020 Aug 28;9(9): [PMID: 32872235]
  56. Antimicrob Agents Chemother. 2015 Nov 16;60(1):580-91 [PMID: 26574006]
  57. FEMS Microbiol Rev. 1993 Sep;12(1-3):39-85 [PMID: 8398217]
  58. Nat Prod Rep. 2021 Sep 23;38(9):1659-1683 [PMID: 33621290]
  59. Infect Dis Rep. 2023 Aug 14;15(4):454-469 [PMID: 37623050]
  60. Mol Biol Rep. 2022 Oct;49(10):10039-10050 [PMID: 35606604]
  61. Antimicrob Agents Chemother. 2016 Jan 04;60(3):1717-24 [PMID: 26729502]
  62. Nat Rev Drug Discov. 2011 Dec 16;11(1):37-51 [PMID: 22173434]
  63. Curr Med Chem. 2011;18(2):256-79 [PMID: 21110801]
  64. Acta Biomater. 2023 Feb;157:210-224 [PMID: 36503077]
  65. Adv Drug Deliv Rev. 2014 Nov 30;78:28-45 [PMID: 25453271]
  66. Antibiotics (Basel). 2023 Jun 10;12(6): [PMID: 37370356]
  67. Int J Mol Sci. 2024 Feb 07;25(4): [PMID: 38396696]
  68. Biochem Biophys Rep. 2023 Jul 10;35:101494 [PMID: 37483312]
  69. Biochem J. 2018 Dec 12;475(23):3903-3915 [PMID: 30541793]
  70. Nat Biotechnol. 2006 Dec;24(12):1551-7 [PMID: 17160061]
  71. Antibiotics (Basel). 2020 Jan 13;9(1): [PMID: 31941022]
  72. Antibiotics (Basel). 2023 Jul 14;12(7): [PMID: 37508284]
  73. Biochem Soc Trans. 2012 Dec 1;40(6):1456-62 [PMID: 23176498]
  74. Microbiology (Reading). 1996 Jul;142 ( Pt 7):1569-80 [PMID: 8757721]
  75. Int J Mol Sci. 2022 Jan 04;23(1): [PMID: 35008974]
  76. Int J Mol Sci. 2024 Jun 29;25(13): [PMID: 39000321]
  77. Nature. 2002 Jan 24;415(6870):389-95 [PMID: 11807545]
  78. Biomolecules. 2018 Jan 19;8(1): [PMID: 29351202]
  79. J Microbiol. 2021 Feb;59(2):113-123 [PMID: 33527313]
  80. Curr Protein Pept Sci. 2015;16(6):549-58 [PMID: 26031307]
  81. Expert Opin Ther Pat. 2020 Dec;30(12):931-947 [PMID: 33187458]
  82. Proc Nutr Soc. 2005 Nov;64(4):465-9 [PMID: 16313688]
  83. Nat Rev Microbiol. 2013 Feb;11(2):95-105 [PMID: 23268227]
  84. Microorganisms. 2020 Apr 27;8(5): [PMID: 32349409]
  85. Cell Chem Biol. 2020 Aug 20;27(8):1032-1051 [PMID: 32698017]
  86. Front Microbiol. 2020 Oct 16;11:582779 [PMID: 33178164]
  87. Microb Ecol. 2023 Dec 1;87(1):8 [PMID: 38036921]
  88. Antibiotics (Basel). 2024 Apr 09;13(4): [PMID: 38667019]
  89. J Pept Sci. 2024 Jan;30(1):e3534 [PMID: 37501572]
  90. Biochem Pharmacol. 2017 Jun 1;133:117-138 [PMID: 27663838]

Grants

  1. Grant NBU-GFSR-27/2024/Central Fund for Strategic Development, New Bulgarian University

MeSH Term

Antimicrobial Peptides
Drug Resistance, Multiple, Bacterial
Humans
Anti-Bacterial Agents
Gram-Negative Bacteria
Gram-Positive Bacteria
Bacteriocins
Bacteria
Animals

Chemicals

Antimicrobial Peptides
Anti-Bacterial Agents
Bacteriocins

Word Cloud

Created with Highcharts 10.0.0AMPsbacteriapathogensbacteriocinsactionAntimicrobialpeptidesBacterialcanproducedGram-negativeGram-positiveantibioticresistancealternativeantibioticsantibacterialbacterialmodesshortusuallycationicamphiphilicstructureallowseasilybindinteractcellularmembranesvirusesfungiviaribosomalsynthesiseliminatecompetingorganismsvitaladdressingincreasingvariouspotentiallyservingineffectiveBacteriocinsnarrowspectrummakinghighlyspecificcompoundstargetparticularreviewcoverstwomaingroupsclassificationsourcespositiveeffectsplayhumanbodylimitationsfutureperspectivesPeptidesDerivedBacteria:ClassificationSourcesMechanismActionMultidrug-ResistantBacteriamechanism

Similar Articles

Cited By (5)